-
Novel Compound Begins Clinical Testing For Potential Treatment Of Multiple Sclerosis
Monday, April 17, 2023 - 3:52pm | 537FSD Pharma Inc. (NASDAQ: HUGE) has dosed the first subjects in its first clinical trial assessing the New Chemical Entity (NCE) Lucid-21-302, or Lucid-MS, targetting multiple sclerosis. The biopharma company is currently developing three drug candidates through its wholly-owned...
-
Awakn's Psychedelics Medical Chief Steps Down, Shifts In Company's Stocks And Ownership
Friday, April 14, 2023 - 12:24pm | 366Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company developing psychedelic therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD) shared its recent corporate news. Dr. Ben Sessa has resigned from his role as Head of Psychedelic Medicine and will transfer...
-
Enveric Creates Subsidiary Down Under To Further Next-Generation Psychedelics Program
Tuesday, March 21, 2023 - 7:30am | 635Drug development biotech company Enveric Biosciences (NASDAQ: ENVB) has created Australia-based subsidiary Enveric Therapeutics Pty. Ltd. to support the progress of its next-generation psychedelics program for anxiety disorders, EVM201, towards the clinical stage. The series includes lead candidate...